THE COST-EFFECTIVENESS OF EXENATIDE BID VERSUS INSULIN LISPRO TID AS ADD-ON THERAPY TO TITRATED INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES - AN ANALYSIS FROM THE SWEDISH HEALTH CARE PERSPECTIVE

被引：0
|
作者：
Gordon, J. [1 ]
McEwan, P. [1 ]
Sabale, U. [2 ]
Kartman, B. [2 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Cardiff, S Glam, Wales
[2] AstraZeneca Nord Balt, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.693
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB70
引用
收藏
页码：A344 / A344
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes
    Gordon, J.
    McEwan, P.
    Sabale, U.
    Kartman, B.
    Wolffenbuttel, B. H. R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1167 - 1174
  • [2] Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
    Braendle, M.
    Erny-Albrecht, K. M.
    Goodall, G.
    Spinas, G. A.
    Streit, P.
    Valentine, W. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (08) : 501 - 515
  • [3] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE TWICE DAILY (BID) VERSUS INSULIN GLARGINE ONCE DAILY (QD) AS ADD-ON THERAPY IN CHINESE PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL THERAPIES
    Deng, J.
    Gu, S.
    Shao, H.
    Dong, H.
    Zhao, Y.
    Shi, L.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A609 - A609
  • [4] Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China
    Gu, Shuyan
    Wang, Xiaoyong
    Qiao, Qing
    Gao, Weiguo
    Wang, Jian
    Dong, Hengjin
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1688 - 1697
  • [5] COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ADDING TWICE-DAILY EXENATIDE TO INSULIN GLARGINE VERSUS ADING INSULIN LISPRO TO TREAT TYPE 2 DIABETES IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Baeten, S.
    Verheggen, B. G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A349 - A349
  • [6] Cost-Effectiveness of Exenatide Twice Daily vs. Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Type 2 Diabetes in China
    Wang, Xiaoyong
    Gu, Shuyan
    Qiao, Qing
    Gao, Weiguo
    Grandy, Susan
    Dong, Hengjin
    [J]. DIABETES, 2016, 65 : A570 - A570
  • [7] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
  • [8] Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies
    Deng, Jing
    Gu, Shuyan
    Shao, Hui
    Dong, Hengjin
    Zou, Dajin
    Shi, Lizheng
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 974 - 989
  • [9] COST-EFFECTIVENESS ANALYSIS OF DULAGLUTIDE COMPARED WITH INSULIN GLARGINE ADD ON TO INSULIN LISPRO IN TREATMENT OF TYPE 2 DIABETES: A US THIRD-PARTY PAYER PERSPECTIVE
    Nili, M.
    Wu, W.
    Kumar, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
  • [10] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
12345